Drug Hunter Journal Club: February 2023
While the Molecules of the Month are being selected and our deep dive reviews are being prepared, you can find early highlights from our team’s journal club from February 2023. Check out AstraZeneca’s preclinical SERD, Merck’s Ph. I c-KIT inhibitor, University of Michigan’s STAT5 PROTAC degrader, and more snippets to jumpstart your reading! Want updates…
Another KRASG12C Inhibitor in Ph. III, Bayer’s Massive FXIa Ph. III Clinical Trial, and 21 Other Molecules in the News
In this update of small molecules in the news for February 2023, we will cover recent: – Molecules in Motion: clinical trial updates and FDA filings – Negative Readouts: halted, discontinued or altered clinical trials – Million-Dollar Molecules: recent M&A’s, IPOs, and other fundraising – Potential Approvals: recent NDA filings and upcoming PDUFA dates – Where…
A Deuterated Ruxolitinib Derivative Among 14 Other Recent Notable Molecules
Here’s a preview of two molecules acquired in January 2023 among 14 mentioned in this article: deuruxolitinib (CTP-543) This molecule, a deuterated version of JAK1/2 inhibitor ruxolitinib (Opzelura, Incyte), has received Breakthrough Therapy designation from the FDA and is being acquired by Sun Pharma via Concert in a $0.576B transaction. The oral molecule is in…
Two Potential Upcoming Approvals and Other January NDAs
Our latest roundup of small molecules in the news includes two potential upcoming approvals: rezafungin Rezafungin (CD-101) is a once-weekly IV antifungal agent and next-generation echinocandin (glucan synthase inhibitor) that demonstrated non-inferiority vs. standard of care caspofungin (IV QD) (NCT03667690). An FDA AdCom voted 14 to 1 in favor that Cidara (CDTX) showed enough evidence…
Molecules of the Month – Where Are They Now? ..and Other Short Stories
Two past Molecules of the Month inductees had significant updates recently, showing they’re still moving forward: obicetrapib This oral, once-daily CETP inhibitor and August ‘22 Molecule of the Month recently met its primary endpoint of LDL-C lowering in a Ph. II study (NCT05266586) in combination with ezetimibe as an adjunct to high-intensity statin therapy. The…
Molecules in Motion: An Oral G12D Inhibitor and Allosteric Cbl-b Inhibitor Entering Development
Our latest roundup of small molecules in the news includes three molecules moving into development for the first time: MRTX1133 Mirati’s reversible, long-acting KRASG12D inhibitor, and December ‘21 Molecule of the Month, is going into the clinic as an oral compound. While initial disclosures referred to its potential as an IV agent, Mirati recently announced…